DASATINIB SUN 100mg tablets medication leaflet

L01EA02 dasatinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | BCR-ABL tyrosine kinase inhibitors

Dasatinibum is a medication used for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with Philadelphia chromosome positivity. It acts as a tyrosine kinase inhibitor, blocking signals that promote cancer cell growth.

The medication is taken orally, usually once daily, and is effective in reducing the number of leukemic cells and prolonging patient survival. It is used in both chronic and advanced phases of the disease.

Side effects may include fluid retention, nausea, diarrhea, fatigue, and muscle pain. In rare cases, severe complications such as pulmonary hypertension or bone marrow suppression may occur. Regular monitoring is essential.

Consult your doctor to discuss the benefits and risks of treatment with Dasatinibum. Follow the prescribed dosage and adhere to all medical recommendations.

General data about DASATINIB SUN 100mg

Substance: dasatinib

Date of last drug list: 01-06-2025

Commercial code: W67862001

Concentration: 100mg

Pharmaceutical form: tablets

Quantity: 30

Product type: generic

Price: 4848.70 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: SUN PHARMACEUTICAL INDUSTRIES EUROPE B.V. - OLANDA

Holder: SUN PHARMACEUTICAL INDUSTRIES EUROPE B.V. - OLANDA

Number: 13873/2021/01

Shelf life: 2 years

Concentrations available for dasatinib

100mg, 111mg, 140mg, 16mg, 20mg, 40mg, 50mg, 55mg, 63mg, 70mg, 79mg, 80mg

Compensation lists for DASATINIB SUN 100mg SUN PHARMACEUTICAL I

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

4848.70 RON

4848.70 RON

0.00 RON